EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Impact of Emicizumab on Coagulation Potential in Plasma From Healthy Women and Carriers of Haemophilia A During Late Pregnancy

Masahiro Takeyama, Fuminori Kimura, Shoko Furukawa, Kana Sasai, Suguru Harada, Tetsuhiro Soeda, Mitsumasa Osuna, Naruto Shimonishi, Yuto Nakajima, Kenichi Ogiwara, Keiji Nogami

Haemophilia · 2026-05 · 32 (3) · 793-800

DOI: 10.1111/hae.70269 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Haemophilia, online erschienen am 23.03.2026. Verfasst von Masahiro Takeyama und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Antibodies, Monoclonal, Humanized, Intracranial Hemorrhages, Hemophilia A. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Chugai Pharmaceutical Co. Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Intra‐cranial haemorrhage (ICH) in neonates with haemophilia A (HA) remains a serious perinatal complication. Prophylactic administration of emicizumab (Emi) to pregnant HA carriers has been discussed as a potential preventive strategy, although current clinical evidence is limited to one case report. This study evaluated whether ex vivo addition of Emi further augments coagulation potential in late pregnancy.

Methods

Plasma samples were obtained from 62 healthy pregnant women and five pregnant HA carriers during late gestation. Emi (50 µg/mL) was added ex vivo, and coagulation potential was assessed using the thrombin generation assay (TGA) and clot waveform analysis (CWA). TGA parameters included time to thrombin peak (ttPeak), peak thrombin (PeakTh) and endogenous thrombin potential (ETP). CWA parameters included clot time (CT) and adjusted coagulation velocity (Ad|min1|).

Results

FVIII activity was elevated in both groups. Emi induced modest shortening of ttPeak in healthy women (9.3–8.5 min) and in carriers (9.3–8.3 min). PeakTh was unchanged in healthy women before and after Emi addition and showed a small reduction in carriers. ETP did not change in healthy women, whereas a slight decrease was observed in carriers. CWA demonstrated a small but statistically significant shortening in CT and increases in Ad|min1| in both groups. Overall, Emi‐induced changes of coagulation potential across assays were modest and generally within assay variability.

Conclusion

These findings ex vivo indicated that Emi at clinically relevant concentrations does not meaningfully enhance the hypercoagulable state characteristic of late pregnancy. In vivo studies are required to confirm the safety of maternal prophylaxis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificAntibodies, Monoclonal, HumanizedIntracranial HemorrhagesHemophilia ABlood CoagulationPregnancy Trimester, ThirdHumansFemalePregnancyHeterozygoteBlood Coagulation TestsYoung AdultAdultTreatment Outcome

Stichwörter der Autor:innen

bispecific antibodycarriercoagulationhaemophilia Apregnant

Substanzen

emicizumabAntibodies, BispecificAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan.
  • Division of Haemophilia, National Hospital Organization, Osaka National Hospital, Osaka, Japan.
  • Department of Obstetrics and Gynecology, Nara Medical University, Kashihara, Nara, Japan.
  • Chugai Pharmaceutical Co. Ltd, Yokohama, Kanagawa, Japan.
  • The Course of Thrombosis and Hemostasis Molecular Pathology, Nara Medical University, Kashihara, Nara, Japan.

Förderung

  • Chugai Pharmaceutical Co. Ltd.

Zitieren

APA

Takeyama, M., Kimura, F., Furukawa, S., Sasai, K., Harada, S., Soeda, T., Osuna, M., Shimonishi, N., Nakajima, Y., Ogiwara, K., & Nogami, K. (2026). Impact of Emicizumab on Coagulation Potential in Plasma From Healthy Women and Carriers of Haemophilia A During Late Pregnancy. Haemophilia, 32(3), 793-800. https://doi.org/10.1111/hae.70269

Vancouver

Takeyama M, Kimura F, Furukawa S, Sasai K, Harada S, Soeda T, et al. Impact of Emicizumab on Coagulation Potential in Plasma From Healthy Women and Carriers of Haemophilia A During Late Pregnancy. Haemophilia. 2026;32(3):793-800. doi:10.1111/hae.70269

BibTeX
@article{Takeyama2026,
  author = {Takeyama, Masahiro and Kimura, Fuminori and Furukawa, Shoko and Sasai, Kana and Harada, Suguru and Soeda, Tetsuhiro and Osuna, Mitsumasa and Shimonishi, Naruto and Nakajima, Yuto and Ogiwara, Kenichi and Nogami, Keiji},
  title = {Impact of Emicizumab on Coagulation Potential in Plasma From Healthy Women and Carriers of Haemophilia A During Late Pregnancy},
  journal = {Haemophilia},
  year = {2026},
  volume = {32},
  number = {3},
  pages = {793--800},
  doi = {10.1111/hae.70269}
}
Kostenlos starten →